AbolerIS Pharma is focused on developing innovative immunomodulators aimed at treating chronic autoimmune and inflammatory diseases. Their lead program features a first-in-class monoclonal antibody that targets CD45RC, which plays a crucial role in rebalancing the immune system. This therapeutic approach is designed to induce immune tolerance while preserving beneficial immune responses, particularly by controlling aggressive T-Effector cells that attack healthy tissues. By enhancing the activity of T Regulatory cells, which function as peacekeepers in the immune response, AbolerIS Pharma aims to provide new treatment options for patients with autoimmune conditions, especially those who have not responded well to existing therapies.

The company's strategy addresses significant clinical challenges, such as the dysregulation of the Teff/Treg cell ratio and the presence of auto-antibodies that contribute to autoimmune disorders. AbolerIS Pharma's monoclonal antibody not only depletes pathogenic T cells and B cells but also preserves memory T and B cells, ensuring that patients maintain immunity against external pathogens. This multifaceted approach aims to modify disease progression, prevent complications, and potentially increase life expectancy for patients suffering from refractory autoimmune diseases. The company has received recognition and funding through various awards and programs, underscoring its commitment to advancing novel immunotherapy solutions.

Belgium

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

Aboleris Pharma

Company Details